Exenatide for Appetite Control
Research, mechanism, dosing, and effectiveness of Exenatide for appetite control.
Quick Answer
GLP-1 activation provides appetite suppression, though less than longer-acting analogs.
Evidence Level
FDA Approved
Typical Dose
5-10 mcg twice daily
Results Timeline
Appetite reduction within first week
FDA Status
FDA Approved
How Exenatide Works for Appetite Control
Acts on brain satiety centers to reduce hunger.
About Appetite Control
Suppression of hunger signals and improved satiety for weight management.
Research Evidence
First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels.
Dosing for Appetite Control
Recommended Dose
5-10 mcg twice daily
Frequency
Twice daily (IR) or once weekly (ER)
Administration
Subcutaneous injection
Duration
Long-term / chronic use
Note: First GLP-1 approved. Byetta (twice daily) or Bydureon (weekly). Must be injected.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (common)
- •Vomiting
- •Diarrhea
- •Dizziness
- •Hypoglycemia
- •Injection site reactions
Frequently Asked Questions
Does Exenatide help with appetite control?
GLP-1 activation provides appetite suppression, though less than longer-acting analogs.
How does Exenatide work for appetite control?
Acts on brain satiety centers to reduce hunger....
What dose of Exenatide should I use for appetite control?
5-10 mcg twice daily
How long until I see results?
Appetite reduction within first week
Other Peptides for Appetite Control
These peptides are also researched for appetite control.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Liraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Dulaglutide
FDAAn FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Educational Information Only
This information about Exenatide for appetite control is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.